Cargando…

Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects

BACKGROUND: With the increasing use of nanomaterials, the need for methods and assays to examine their immunosafety is becoming urgent, in particular for nanomaterials that are deliberately administered to human subjects (as in the case of nanomedicines). To obtain reliable results, standardised in...

Descripción completa

Detalles Bibliográficos
Autores principales: Oostingh, Gertie J, Casals, Eudald, Italiani, Paola, Colognato, Renato, Stritzinger, René, Ponti, Jessica, Pfaller, Tobias, Kohl, Yvonne, Ooms, Daniëlla, Favilli, Flavia, Leppens, Hilde, Lucchesi, Davide, Rossi, François, Nelissen, Inge, Thielecke, Hagen, Puntes, Victor F, Duschl, Albert, Boraschi, Diana
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3045340/
https://www.ncbi.nlm.nih.gov/pubmed/21306632
http://dx.doi.org/10.1186/1743-8977-8-8
_version_ 1782198815330140160
author Oostingh, Gertie J
Casals, Eudald
Italiani, Paola
Colognato, Renato
Stritzinger, René
Ponti, Jessica
Pfaller, Tobias
Kohl, Yvonne
Ooms, Daniëlla
Favilli, Flavia
Leppens, Hilde
Lucchesi, Davide
Rossi, François
Nelissen, Inge
Thielecke, Hagen
Puntes, Victor F
Duschl, Albert
Boraschi, Diana
author_facet Oostingh, Gertie J
Casals, Eudald
Italiani, Paola
Colognato, Renato
Stritzinger, René
Ponti, Jessica
Pfaller, Tobias
Kohl, Yvonne
Ooms, Daniëlla
Favilli, Flavia
Leppens, Hilde
Lucchesi, Davide
Rossi, François
Nelissen, Inge
Thielecke, Hagen
Puntes, Victor F
Duschl, Albert
Boraschi, Diana
author_sort Oostingh, Gertie J
collection PubMed
description BACKGROUND: With the increasing use of nanomaterials, the need for methods and assays to examine their immunosafety is becoming urgent, in particular for nanomaterials that are deliberately administered to human subjects (as in the case of nanomedicines). To obtain reliable results, standardised in vitro immunotoxicological tests should be used to determine the effects of engineered nanoparticles on human immune responses. However, before assays can be standardised, it is important that suitable methods are established and validated. RESULTS: In a collaborative work between European laboratories, existing immunological and toxicological in vitro assays were tested and compared for their suitability to test effects of nanoparticles on immune responses. The prototypical nanoparticles used were metal (oxide) particles, either custom-generated by wet synthesis or commercially available as powders. Several problems and challenges were encountered during assay validation, ranging from particle agglomeration in biological media and optical interference with assay systems, to chemical immunotoxicity of solvents and contamination with endotoxin. CONCLUSION: The problems that were encountered in the immunological assay systems used in this study, such as chemical or endotoxin contamination and optical interference caused by the dense material, significantly affected the data obtained. These problems have to be solved to enable the development of reliable assays for the assessment of nano-immunosafety.
format Text
id pubmed-3045340
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30453402011-02-26 Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects Oostingh, Gertie J Casals, Eudald Italiani, Paola Colognato, Renato Stritzinger, René Ponti, Jessica Pfaller, Tobias Kohl, Yvonne Ooms, Daniëlla Favilli, Flavia Leppens, Hilde Lucchesi, Davide Rossi, François Nelissen, Inge Thielecke, Hagen Puntes, Victor F Duschl, Albert Boraschi, Diana Part Fibre Toxicol Methodology BACKGROUND: With the increasing use of nanomaterials, the need for methods and assays to examine their immunosafety is becoming urgent, in particular for nanomaterials that are deliberately administered to human subjects (as in the case of nanomedicines). To obtain reliable results, standardised in vitro immunotoxicological tests should be used to determine the effects of engineered nanoparticles on human immune responses. However, before assays can be standardised, it is important that suitable methods are established and validated. RESULTS: In a collaborative work between European laboratories, existing immunological and toxicological in vitro assays were tested and compared for their suitability to test effects of nanoparticles on immune responses. The prototypical nanoparticles used were metal (oxide) particles, either custom-generated by wet synthesis or commercially available as powders. Several problems and challenges were encountered during assay validation, ranging from particle agglomeration in biological media and optical interference with assay systems, to chemical immunotoxicity of solvents and contamination with endotoxin. CONCLUSION: The problems that were encountered in the immunological assay systems used in this study, such as chemical or endotoxin contamination and optical interference caused by the dense material, significantly affected the data obtained. These problems have to be solved to enable the development of reliable assays for the assessment of nano-immunosafety. BioMed Central 2011-02-09 /pmc/articles/PMC3045340/ /pubmed/21306632 http://dx.doi.org/10.1186/1743-8977-8-8 Text en Copyright ©2011 Oostingh et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Methodology
Oostingh, Gertie J
Casals, Eudald
Italiani, Paola
Colognato, Renato
Stritzinger, René
Ponti, Jessica
Pfaller, Tobias
Kohl, Yvonne
Ooms, Daniëlla
Favilli, Flavia
Leppens, Hilde
Lucchesi, Davide
Rossi, François
Nelissen, Inge
Thielecke, Hagen
Puntes, Victor F
Duschl, Albert
Boraschi, Diana
Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects
title Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects
title_full Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects
title_fullStr Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects
title_full_unstemmed Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects
title_short Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects
title_sort problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects
topic Methodology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3045340/
https://www.ncbi.nlm.nih.gov/pubmed/21306632
http://dx.doi.org/10.1186/1743-8977-8-8
work_keys_str_mv AT oostinghgertiej problemsandchallengesinthedevelopmentandvalidationofhumancellbasedassaystodeterminenanoparticleinducedimmunomodulatoryeffects
AT casalseudald problemsandchallengesinthedevelopmentandvalidationofhumancellbasedassaystodeterminenanoparticleinducedimmunomodulatoryeffects
AT italianipaola problemsandchallengesinthedevelopmentandvalidationofhumancellbasedassaystodeterminenanoparticleinducedimmunomodulatoryeffects
AT colognatorenato problemsandchallengesinthedevelopmentandvalidationofhumancellbasedassaystodeterminenanoparticleinducedimmunomodulatoryeffects
AT stritzingerrene problemsandchallengesinthedevelopmentandvalidationofhumancellbasedassaystodeterminenanoparticleinducedimmunomodulatoryeffects
AT pontijessica problemsandchallengesinthedevelopmentandvalidationofhumancellbasedassaystodeterminenanoparticleinducedimmunomodulatoryeffects
AT pfallertobias problemsandchallengesinthedevelopmentandvalidationofhumancellbasedassaystodeterminenanoparticleinducedimmunomodulatoryeffects
AT kohlyvonne problemsandchallengesinthedevelopmentandvalidationofhumancellbasedassaystodeterminenanoparticleinducedimmunomodulatoryeffects
AT oomsdaniella problemsandchallengesinthedevelopmentandvalidationofhumancellbasedassaystodeterminenanoparticleinducedimmunomodulatoryeffects
AT favilliflavia problemsandchallengesinthedevelopmentandvalidationofhumancellbasedassaystodeterminenanoparticleinducedimmunomodulatoryeffects
AT leppenshilde problemsandchallengesinthedevelopmentandvalidationofhumancellbasedassaystodeterminenanoparticleinducedimmunomodulatoryeffects
AT lucchesidavide problemsandchallengesinthedevelopmentandvalidationofhumancellbasedassaystodeterminenanoparticleinducedimmunomodulatoryeffects
AT rossifrancois problemsandchallengesinthedevelopmentandvalidationofhumancellbasedassaystodeterminenanoparticleinducedimmunomodulatoryeffects
AT nelisseninge problemsandchallengesinthedevelopmentandvalidationofhumancellbasedassaystodeterminenanoparticleinducedimmunomodulatoryeffects
AT thieleckehagen problemsandchallengesinthedevelopmentandvalidationofhumancellbasedassaystodeterminenanoparticleinducedimmunomodulatoryeffects
AT puntesvictorf problemsandchallengesinthedevelopmentandvalidationofhumancellbasedassaystodeterminenanoparticleinducedimmunomodulatoryeffects
AT duschlalbert problemsandchallengesinthedevelopmentandvalidationofhumancellbasedassaystodeterminenanoparticleinducedimmunomodulatoryeffects
AT boraschidiana problemsandchallengesinthedevelopmentandvalidationofhumancellbasedassaystodeterminenanoparticleinducedimmunomodulatoryeffects